June 15, 2020 / 12:18 PM / 2 months ago

BRIEF-Bellicum Receives FDA IND Clearance To Initiate Phase 1/2 Clinical Trial For BPX-603

June 15 (Reuters) - Bellicum Pharmaceuticals Inc:

* BELLICUM RECEIVES FDA IND CLEARANCE TO INITIATE A PHASE 1/2 CLINICAL TRIAL FOR BPX-603, A DUAL-SWITCH GOCAR-T® FOR HER2+ SOLID TUMORS

* BELLICUM PHARMACEUTICALS INC - TO INITIATE PHASE 1/2 TRIAL WITH BPX-603 TARGETING SOLID TUMORS THAT EXPRESS HER2 LATER IN 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below